#USA #New York #Everest Group #ACTO #Pharmaceutical Technology

ACTO's Inclusion in Everest Group's Top 50™ Pharmaceutical Technology Providers

In a significant recognition underscoring its leadership, ACTO has been included in Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026. This global list showcases the foremost technology providers servicing the pharmaceutical value chain.

Founded on the fusion of human intelligence with empathetic AI, ACTO specializes in life sciences and has proven its capabilities by aligning its pioneering technology solutions with the growing demands of the industry. The Everest Group's Top 50™ report offers a thorough snapshot of the pharmaceutical technology landscape, spotlighting key trends among which are AI-driven insights, cloud-native capabilities, and the necessity for strategic partnerships.

As the pharmaceutical sector amplifies investment in technologies aimed at enhancing commercial and medical execution, the demand for omnichannel enablement is surging. This inclusion reflects ACTO’s commitment to bridging fragmented data and systems while adhering to the necessary governance, traceability, and compliance required in regulated environments.

Durga Ambati, Vice President of the Everest Group, stated, “As pharmaceutical companies transition from the digitization of isolated workflows to an integrated execution powered by AI, they are prioritizing technology platforms capable of incorporating fragmented data and systems while ensuring regulatory compliance.”

The recognition of ACTO, particularly at this pivotal juncture for the life sciences industry, reinforces its status as a frontrunner thanks to consistent investments in AI technologies designed for knowledge assistance, simulated training, and workflow automation. Its integrations with platforms like Veeva and Salesforce further solidify ACTO's position within the commercial technology ecosystem.

The report emphasizes the rapid shift towards AI-enabled management capabilities as pharmaceutical technology progresses beyond peripheral systems to targeted agents that can orchestrate complex workflows under regulated controls. Notably, the commercial and medical interactions are identified as the primary areas for this implementation.

This evolution works in tandem with ACTO's strategy. Exclusively focused on the life sciences, ACTO has harnessed its AI-native platform alongside role-based super agents aimed at empowering customer service professionals. This focus allows them to operate more efficiently, confidently, and impactful.

Parth Khanna, co-founder and CEO of ACTO, expressed gratitude to the Everest Group for this acknowledgment, stating, “Since day one, our exclusive concentration on Life Sciences has enabled us to deeply understand the people, workflows, systems, and regulatory realities that make the industry unique. Integrating this expertise into our AI-native platform and role-based AI underscores our commitment to continuous innovation and shaping the future of excellence within the life sciences sector.”

The Everest Group evaluates providers based on a weighted composite score across four key parameters:
1. Market Adoption and Scale (45%) - considers pharmaceutical business revenue, customer base, and value chain coverage.
2. Innovation, Investment, and Partnerships (30%) - emphasizes AI integration, cloud capabilities, and strategic alliances.
3. Value Generation and Outcomes (15%) - assesses the impact and value delivered to pharmaceutical clients.
4. Clients and Geographic Coverage (10%) - evaluates global presence and client mix.

Those interested in reading the full Everest Group report can find it under the title Top 50™ Pharmaceutical Technology Providers 2026. Additionally, to learn how ACTO enhances field readiness, operational efficiency, and customer interaction, engagement can be sought via direct contact or by visiting booth number 508 during Fierce Pharma Week in Philadelphia.

For further information, visit www.acto.com. You can also follow ACTO on LinkedIn for the latest updates and news about the company.

About Everest Group

Everest Group is a leading global research firm that enables business leaders to make confident decisions. Their PEAK Matrix® evaluations provide the analysis and insights needed to make crucial selection decisions regarding global service providers, locations, products, and solutions across various market segments. Service providers utilize the PEAK Matrix® to benchmark and compare their offerings against competitors within the industry. More information and in-depth content can be found at www.everestgrp.com.

About ACTO

Trusted by 14 of the top 50 pharmaceutical and high-growth biotech companies, ACTO is redefining how therapies reach patients following regulatory approval. By combining human intelligence with empathetic AI through their AI-powered field excellence platform and AI super agents, ACTO accelerates product launches, strengthens field execution, and deepens customer interactions. By uplifting training and coaching, and enabling up to 30% of integrated roles focused on customer interaction, ACTO frees teams to prioritize what matters most—human connection, judgment, and strategic execution. Designed to comply with the highest regulatory standards in the industry, ACTO is FDA 21 CFR Part 11 validated and SOC 2 Type II certified. Learn more at www.acto.com.